Disease Burden

Prevalence and Incidence

Determining the epidemiology of PSVT requires an understanding of the strengths and limitations of existing U.S. population-based research.

A challenge is that a definitive diagnosis of PSVT can only be made by documenting the rhythm during an episode, whether that is by an ECG, a hospital or ED monitor, an outpatient, wearable monitor (e.g., Holter monitor or event recorder), or an implantable device. However, given the transient and episodic nature of PSVT, only a quarter of cases document PSVT upon the first symptomatic episode.4

This means that PSVT prevalence estimates relying on a single medical encounter may be an underestimation. The studies below predict prevalence ranges between 393,810 and 570,000.

Longitudinal analyses may be more appropriate in estimating the number of Americans affected by PSVT, given its diagnosis journey and the clinical course. Using estimates from Medicare claims data for patients age 65 and older and employer-based medical claims data for patients under age 65, projected prevalence for all ages is reported to be greater than 1.7 million based on an analysis of claims between 2012 and 2016. These numbers are calculated using the maximum positive predictive values (PPV) weight from Go et al. The results were recently published as an abstract in Cardiology accompanied by an oral presentation at the 2018 International Academy of Cardiology’s Scientific Sessions. Both resources are available below.

Healthcare Economics

Current treatment approaches for PSVT are associated with a large burden on providers and have a high economic burden for payers.

Longitudinal analyses of Medicare and employer-based medical claims data can also be used to estimate healthcare resource utilization (HRU) for PSVT patients. Such analyses have been performed with a dataset spanning 2008 to 2016, from which it is estimated that more than 600,000 PSVT patients submit claims for PSVT each year (reference: data on file). In addition, these analyses show that PSVT patients in the US visit the emergency department or get admitted to the hospital in excess of 170,000 times per year, and approximately 80,000 per year get a catheter ablation for their condition (reference: data on file)

Furthermore, a recent analysis, available below, concluded healthcare spending increases substantially compared with matched controls, both in the year prior to diagnosis and especially in the year following diagnosis of PSVT in commercially insured patients.

References

  1. Orejarena, L.A. J Am Coll Cardiol. 1998;31(1):150-7.